Genenta Science S.p.A.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.

Medicenna Therapeutics Corp.MDNAF · BiotechToronto, Canada

68% matchPublic

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

GolgeniaBiotechItaly

67% match

Golgenia is a research and development company operating in the drug discovery industry and advancing its GSL oncology platform. Headquartered in Milan, Italy, the company closed a 1.5 million euro Series A financing to support its pipeline toward first-in-human trials.

Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma. Additionally, NEO212, a unique molecular construct chemically linking the chemotherapeutic agent temozolomide with perillyl alcohol, has successfully concluded its preclinical evaluation. This enterprise, founded in 2023, operates from its base in Los Angeles, California.

GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of cancer immunotherapies, with operations spanning the United States, Germany, and the rest of Europe. The company's primary investigational therapy, AFM13, has successfully completed a Phase II clinical study for peripheral T-cell lymphoma. This same candidate is also currently undergoing Phase IIa clinical trials for CD30-positive lymphoma and is in Phase I trials for Hodgkin lymphoma. Beyond its lead product, Affimed is advancing several other promising pipeline compounds. AFM24, a tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptors and CD16A, is presently in Phase IIa clinical trials for the treatment of various advanced cancers. Additionally, two other innate cell engagers (ICEs) are in preclinical development: AFM28, which is being investigated for acute myeloid leukemia, and AFM32, a candidate focused on the treatment of solid tumors. Affimed N.V. has formed strategic partnerships with esteemed institutions and companies, including The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. The company also receives research funding through an agreement with The Leukemia & Lymphoma Society. Founded in 2000, Affimed N.V. was initially known as Affimed Therapeutics B.V. before officially changing its name in October 2014. Its corporate headquarters are located in Heidelberg, Germany.